Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications (524 views)
Head Neck-J Sci Spec (ISSN: 1043-3074), 2015; 37(5): 763-770.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 2.76, 5-year impact factor: 2.79
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84923165976&partnerID=40&md5=89fab1b27b11d1f8ea1684046db28847
Keywords: Akt, P53, Chemoradiotherapy, Epidermal Growth Factor Receptor (egfr), Head And Neck Squamous Cell Carcinoma, Intracellular Pathway, Radioresistance, Adenovirus Vector, Amphiregulin, Bevacizumab, Cetuximab, Contusugene Ladenovec, Cyclin D1, Dactolisib, Docetaxel, Erlotinib, Initiation Factor 4e, K Ras Protein, Lontucirev, Mammalian Target Of Rapamycin, Methotrexate, Perifosine, Phosphatidylinositol 3 Kinase, Protein Bax, Protein Kinase B, Protein P53, Puma Protein, Temsirolimus, Tipifarnib, Transforming Growth Factor, Unindexed Drug, Uvomorulin, Vorinostat, [1 (4 Oxo 8 Phenyl 4h 1 Benzopyran 2 Yl)morpholinio]methoxysuccinylarginylglycylaspartylserine Acetate, Advanced Cancer, Apoptosis, Article, Autophosphorylation, Cancer Radiotherapy, Cancer Recurrence, Cell Migration, Cell Proliferation, Cell Survival, Dna Damage, Dna Repair, Down Regulation, Enzyme Inhibition, Enzyme Phosphorylation, Epithelial Mesenchymal Transition, G1 Phase Cell Cycle Checkpoint, Gene Mutation, Gene Overexpression, Human, Immunohistochemistry, Ionizing Radiation, Papillomavirus Infection, Priority Journal, Radiation Dose Fractionation, Radiosensitivity, Signal Transduction, T Lymphocyte Activation, Upregulation, Viral Gene Therapy, Virus Replication, Wild Type, Egfr Protein, Mtor Protein, Target Of Rapamycin Kinase, Drug Effects, Female, Head And Neck Neoplasms, Molecularly Targeted Therapy, Pathology, Physiology, Procedures, Prognosis, Radiation Response, Risk Assessment, Treatment Outcome, Molecular Targeted Therapy, Radiation Tolerance, Radiotherapy Dosage, Tor Serine-Threonine Kinases,
Affiliations:
*** IBB - CNR ***
Head and Neck Medical Oncology Unit, National Tumor Institute of Naples, Naples, Italy.
Institute of Biostructures and Bioimaging, National Council of Research (CNR)Naples Italy
Department of Advanced Biomedical SciencesUniversity Federico IINaples Italy
Department of Clinical Medicine and SurgeryUniversity Federico IINaples Italy
Lester and Sue Smith Breast Center, Baylor College of MedicineHouston Texas
Department of Medical OncologyUniversity of SalernoSalerno Italy
References:
Ang, K.K., Andratschke, N.H., Milas, L., Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy (2004) Int J Radiat Oncol Biol Phys, 58, pp. 959-96
(2013), http://www.nccn.org/professionals/physician_gls/f_guidelines.asp, NCCN guidelines. Accessed January 4Pignon, J.P., Le Maître, A., Maillard, E., Bourhis, J., Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients (2009) Radiother Oncol, 92, pp. 4-14. , MACH-NC Collaborative Group
Ang, K.K., Berkey, B.A., Tu, X., Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma (2002) Cancer Res, 62, pp. 7350-7356
Freudlsperger, C., Burnett, J.R., Friedman, J.A., Kannabiran, V.R., Chen, Z., Van Waes, C., EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: Attractive targets for molecular-oriented therapy (2011) Expert Opin Ther Targets, 15, pp. 63-74
Kumar, R., Hung, M.C., Signaling intricacies take center stage in cancer cells (2005) Cancer Res, 65, pp. 2511-2515
Bussink, J., Van Der Kogel, A.J., Kaanders, J.H., Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer (2008) Lancet Oncol, 9, pp. 288-296
Hama, T., Yuza, Y., Saito, Y., Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma (2009) Oncologist, 14, pp. 900-908
Eriksen, J.G., Steiniche, T., Askaa, J., Alsner, J., Overgaard, J., The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck (2004) Int J Radiat Oncol Biol Phys, 58, pp. 561-566
Zhu, X., Zhang, F., Zhang, W., He, J., Zhao, Y., Chen, X., Prognostic role of epidermal growth factor receptor in head and neck cancer: A meta-analysis (2013) J Surg Oncol, 108, pp. 387-397
Sun, W., Long, G., Wang, J., Mei, Q., Liu, D., Hu, G., Prognostic role of epidermal growth factor receptor in nasopharyngeal carcinoma: A meta-analysis (2013) Head Neck, , [Epub ahead of print]
Hoogsteen, I.J., Marres, H.A., Van Den Hoogen, F.J., Expression of EGFR under tumor hypoxia: Identification of a subpopulation of tumor cells responsible for aggressiveness and treatment resistance (2012) Int J Radiat Oncol Biol Phys, 84, pp. 807-814
Saki, M., Toulany, M., Rodemann, H.P., Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells (2013) Radiother Oncol, 108, pp. 473-478
Overgaard, J., Hansen, H.S., Specht, L., Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial (2003) Lancet, 362, pp. 933-940
Corvò, R., Evidence-based radiation oncology in head and neck squamous cell carcinoma (2007) Radiother Oncol, 85, pp. 156-170
Bentzen, S.M., Atasoy, B.M., Daley, F.M., Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial (2005) J Clin Oncol, 23, pp. 5560-5567
Pedicini, P., Nappi, A., Strigari, L., Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma (2012) Radiat Oncol, 7, p. 143
Bonner, J.A., Harari, P.M., Giralt, J., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck (2006) N Engl J Med, 354, pp. 567-578
Awada, A., Zhang, S., Gil, T., A phase i clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies (2007) Curr Med Res Opin, 23, pp. 991-1003
Li, S., Takasu, T., Perlman, D.M., Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release (2003) J Biol Chem, 278, pp. 3015-3022
Hong, K.O., Kim, J.H., Hong, J.S., Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells (2009) J Exp Clin Cancer Res, 28, p. 28
Bruzzese, F., Leone, A., Rocco, M., HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT (2011) J Cell Physiol, 226, pp. 2378-2390
Toulany, M., Baumann, M., Rodemann, H.P., Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity (2007) Mol Cancer Res, 5, pp. 863-872
Dent, P., Yacoub, A., Contessa, J., Stress and radiation-induced activation of multiple intracellular signaling pathways (2003) Radiat Res, 159, pp. 283-300
Qiu, W., Schönleben, F., Li, X., PIK3CA mutations in head and neck squamous cell carcinoma (2006) Clin Cancer Res, 12, pp. 1441-1446
Lui, V.W., Hedberg, M.L., Li, H., Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers (2013) Cancer Discov, 3, pp. 761-769
Yoshida, K., Sasaki, R., Nishimura, H., Nuclear factor-kappaB expression as a novel marker of radioresistance in early-stage laryngeal cancer (2010) Head Neck, 32, pp. 646-655
Alshareeda, A.T., Negm, O.H., Albarakati, N., Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer (2013) Breast Cancer Res Treat, 139, pp. 301-310
Groselj, B., Kerr, M., Kiltie, A.E., Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression (2013) Radiother Oncol, 108, pp. 429-433
Kuo, M.L., Chuang, S.E., Lin, M.T., Yang, S.Y., The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6 (2001) Oncogene, 20, pp. 677-685
Zhan, M., Han, Z.C., Phosphatidylinositide 3-kinase/AKT in radiation responses (2004) Histol Histopathol, 19, pp. 915-923
Wymann, M.P., Bulgarelli-Leva, G., Zvelebil, M.J., Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction (1996) Mol Cell Biol, 16, pp. 1722-1733
Vlahos, C.J., Matter, W.F., Hui, K.Y., Brown, R.F., A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) (1994) J Biol Chem, 269, pp. 5241-5248
Garlich, J.R., De, P., Dey, N., A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity (2008) Cancer Res, 68, pp. 206-215
Ma, B.B., Lui, V.W., Hui, C.W., Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models (2014) Cancer Lett, 343, pp. 24-32
Hideshima, T., Catley, L., Yasui, H., Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells (2006) Blood, 107, pp. 4053-4062
Argiris, A., Cohen, E., Karrison, T., A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer (2006) Cancer Biol Ther, 5, pp. 766-770
Bauman, J.E., Arias-Pulido, H., Lee, S.J., A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma (2013) Oral Oncol, 49, pp. 461-467
Bhatt, V.R., Ganti, A.K., Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck (2013) Oral Oncol, 49, p. e25
Brown, C.J., Lain, S., Verma, C.S., Fersht, A.R., Lane, D.P., Awakening guardian angels: Drugging the p53 pathway (2009) Nat Rev Cancer, 9, pp. 862-873
Vousden, K.H., Lu, X., Live or let die: The cell's response to p53 (2002) Nat Rev Cancer, 2, pp. 594-604
Gasco, M., Crook, T., The p53 network in head and neck cancer (2003) Oral Oncol, 39, pp. 222-231
Murphy, M., Ahn, J., Walker, K.K., Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a (1999) Genes Dev, 13, pp. 2490-2501
Mihara, M., Erster, S., Zaika, A., P53 has a direct apoptogenic role at the mitochondria (2003) Mol Cell, 11, pp. 577-590
Yu, J., Zhang, L., PUMA, a potent killer with or without p53 (2008) Oncogene, 271, pp. S71-S83
Somers, K.D., Merrick, M.A., Lopez, M.E., Incognito, L.S., Schechter, G.L., Casey, G., Frequent p53 mutations in head and neck cancer (1992) Cancer Res, 52, pp. 5997-6000
Couture, C., Raybaud-Diogène, H., Têtu, B., P53 and Ki-67 as markers of radioresistance in head and neck carcinoma (2002) Cancer, 94, pp. 713-722
Skinner, H.D., Sandulache, V.C., Ow, T.J., TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence (2012) Clin Cancer Res, 18, pp. 290-300
Poeta, M.L., Manola, J., Goldwasser, M.A., TP53 mutations and survival in squamous-cell carcinoma of the head and neck (2007) N Engl J Med, 357, pp. 2552-2561
Csuka, O., Remenár, E., Koronczay, K., Doleschall, Z., Németh, G., Predictive value of p53, Bcl2 and bax in the radiotherapy of head and neck cancer (1997) Pathol Oncol Res, 3, pp. 204-210
Valente, L.J., Gray, D.H., Michalak, E.M., P53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa (2013) Cell Rep, 3, pp. 1339-1345
Yoo, G.H., Moon, J., Leblanc, M., A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: Report of the Southwest Oncology Group (2009) Arch Otolaryngol Head Neck Surg, 135, pp. 869-874
Clayman, G.L., El-Naggar, A.K., Lippman, S.M., Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma (1998) J Clin Oncol, 16, pp. 2221-2232
Nemunaitis, J., Nemunaitis, J., Head and neck cancer: Response to p53-based therapeutics (2011) Head Neck, 33, pp. 131-134
Pearson, S., Jia, H., Kandachi, K., China approves first gene therapy (2004) Nat Biotechnol, 22, pp. 3-4
Tassone, P., Old, M., Teknos, T.N., Pan, Q., P53-based therapeutics for head and neck squamous cell carcinoma (2013) Oral Oncol, 49, pp. 733-737
Nemunaitis, J., Khuri, F., Ganly, I., Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer (2001) J Clin Oncol, 19, pp. 289-298
Ganly, I., Kirn, D., Eckhardt, G., A phase i study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer (2000) Clin Cancer Res, 6, pp. 798-806
Yuki, K., Takahashi, A., Ota, I., Sensitization by glycerol for CDDP-therapy against human cultured cancer cells and tumors bearing mutated p53 gene (2004) Apoptosis, 9, pp. 853-859
Ota, I., Okamoto, N., Yane, K., Therapeutic strategies for head and neck cancer based on p53 status (2012) Exp Ther Med, 3, pp. 585-591
Bykov, V.J., Issaeva, N., Shilov, A., Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound (2002) Nat Med, 8, pp. 282-288
Roh, J.L., Kang, S.K., Minn, I., Califano, J.A., Sidransky, D., Koch, W.M., P53-reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma (2011) Oral Oncol, 47, pp. 8-15
Xie, X., Piao, L., Bullock, B.N., Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma (2014) Oncogene, 33, pp. 1037-1046
Smokeless tobacco and some tobacco-specific N-nitrosamines (2007) IARC Monogr Eval Carcinog Risks Hum, 89, pp. 1-592. , Working Group On The Evaluation Of Carcinogenic Risks To Humans I
Park, B.J., Chiosea, S.I., Grandis, J.R., Molecular changes in the multistage pathogenesis of head and neck cancer (2010) Cancer Biomark, 9, pp. 325-339
Lassen, P., Eriksen, J.G., Hamilton-Dutoit, S., Tramm, T., Alsner, J., Overgaard, J., Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck (2009) J Clin Oncol, 27, pp. 1992-1998
Cattani, P., Hohaus, S., Bellacosa, A., Association between cyclin D1 (CCND1) gene amplification and human papillomavirus infection in human laryngeal squamous cell carcinoma (1998) Clin Cancer Res, 4, pp. 2585-2589
Kostareli, E., Holzinger, D., Hess, J., New concepts for translational head and neck oncology: Lessons from HPV-related oropharyngeal squamous cell carcinomas (2012) Front Oncol, 2, p. 36
Licitra, L., Perrone, F., Bossi, P., High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma (2006) J Clin Oncol, 24, pp. 5630-5636
Kofler, B., Laban, S., Busch, C.J., Lörincz, B., Knecht, R., New treatment strategies for HPV-positive head and neck cancer (2014) Eur Arch Otorhinolaryngol, 271, pp. 1861-1867
Pajares, B., Trigo, J.M., Toledo, M.D., Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer (2013) BMC Cancer, 13, p. 26
Head Neck-J Sci Spec (ISSN: 1043-3074), 2015; 37(5): 763-770.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 2.76, 5-year impact factor: 2.79
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84923165976&partnerID=40&md5=89fab1b27b11d1f8ea1684046db28847
Keywords: Akt, P53, Chemoradiotherapy, Epidermal Growth Factor Receptor (egfr), Head And Neck Squamous Cell Carcinoma, Intracellular Pathway, Radioresistance, Adenovirus Vector, Amphiregulin, Bevacizumab, Cetuximab, Contusugene Ladenovec, Cyclin D1, Dactolisib, Docetaxel, Erlotinib, Initiation Factor 4e, K Ras Protein, Lontucirev, Mammalian Target Of Rapamycin, Methotrexate, Perifosine, Phosphatidylinositol 3 Kinase, Protein Bax, Protein Kinase B, Protein P53, Puma Protein, Temsirolimus, Tipifarnib, Transforming Growth Factor, Unindexed Drug, Uvomorulin, Vorinostat, [1 (4 Oxo 8 Phenyl 4h 1 Benzopyran 2 Yl)morpholinio]methoxysuccinylarginylglycylaspartylserine Acetate, Advanced Cancer, Apoptosis, Article, Autophosphorylation, Cancer Radiotherapy, Cancer Recurrence, Cell Migration, Cell Proliferation, Cell Survival, Dna Damage, Dna Repair, Down Regulation, Enzyme Inhibition, Enzyme Phosphorylation, Epithelial Mesenchymal Transition, G1 Phase Cell Cycle Checkpoint, Gene Mutation, Gene Overexpression, Human, Immunohistochemistry, Ionizing Radiation, Papillomavirus Infection, Priority Journal, Radiation Dose Fractionation, Radiosensitivity, Signal Transduction, T Lymphocyte Activation, Upregulation, Viral Gene Therapy, Virus Replication, Wild Type, Egfr Protein, Mtor Protein, Target Of Rapamycin Kinase, Drug Effects, Female, Head And Neck Neoplasms, Molecularly Targeted Therapy, Pathology, Physiology, Procedures, Prognosis, Radiation Response, Risk Assessment, Treatment Outcome, Molecular Targeted Therapy, Radiation Tolerance, Radiotherapy Dosage, Tor Serine-Threonine Kinases,
Affiliations:
*** IBB - CNR ***
Head and Neck Medical Oncology Unit, National Tumor Institute of Naples, Naples, Italy.
Institute of Biostructures and Bioimaging, National Council of Research (CNR)Naples Italy
Department of Advanced Biomedical SciencesUniversity Federico IINaples Italy
Department of Clinical Medicine and SurgeryUniversity Federico IINaples Italy
Lester and Sue Smith Breast Center, Baylor College of MedicineHouston Texas
Department of Medical OncologyUniversity of SalernoSalerno Italy
References:
Ang, K.K., Andratschke, N.H., Milas, L., Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy (2004) Int J Radiat Oncol Biol Phys, 58, pp. 959-96
(2013), http://www.nccn.org/professionals/physician_gls/f_guidelines.asp, NCCN guidelines. Accessed January 4Pignon, J.P., Le Maître, A., Maillard, E., Bourhis, J., Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients (2009) Radiother Oncol, 92, pp. 4-14. , MACH-NC Collaborative Group
Ang, K.K., Berkey, B.A., Tu, X., Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma (2002) Cancer Res, 62, pp. 7350-7356
Freudlsperger, C., Burnett, J.R., Friedman, J.A., Kannabiran, V.R., Chen, Z., Van Waes, C., EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: Attractive targets for molecular-oriented therapy (2011) Expert Opin Ther Targets, 15, pp. 63-74
Kumar, R., Hung, M.C., Signaling intricacies take center stage in cancer cells (2005) Cancer Res, 65, pp. 2511-2515
Bussink, J., Van Der Kogel, A.J., Kaanders, J.H., Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer (2008) Lancet Oncol, 9, pp. 288-296
Hama, T., Yuza, Y., Saito, Y., Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma (2009) Oncologist, 14, pp. 900-908
Eriksen, J.G., Steiniche, T., Askaa, J., Alsner, J., Overgaard, J., The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck (2004) Int J Radiat Oncol Biol Phys, 58, pp. 561-566
Zhu, X., Zhang, F., Zhang, W., He, J., Zhao, Y., Chen, X., Prognostic role of epidermal growth factor receptor in head and neck cancer: A meta-analysis (2013) J Surg Oncol, 108, pp. 387-397
Sun, W., Long, G., Wang, J., Mei, Q., Liu, D., Hu, G., Prognostic role of epidermal growth factor receptor in nasopharyngeal carcinoma: A meta-analysis (2013) Head Neck, , [Epub ahead of print]
Hoogsteen, I.J., Marres, H.A., Van Den Hoogen, F.J., Expression of EGFR under tumor hypoxia: Identification of a subpopulation of tumor cells responsible for aggressiveness and treatment resistance (2012) Int J Radiat Oncol Biol Phys, 84, pp. 807-814
Saki, M., Toulany, M., Rodemann, H.P., Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells (2013) Radiother Oncol, 108, pp. 473-478
Overgaard, J., Hansen, H.S., Specht, L., Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial (2003) Lancet, 362, pp. 933-940
Corvò, R., Evidence-based radiation oncology in head and neck squamous cell carcinoma (2007) Radiother Oncol, 85, pp. 156-170
Bentzen, S.M., Atasoy, B.M., Daley, F.M., Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial (2005) J Clin Oncol, 23, pp. 5560-5567
Pedicini, P., Nappi, A., Strigari, L., Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma (2012) Radiat Oncol, 7, p. 143
Bonner, J.A., Harari, P.M., Giralt, J., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck (2006) N Engl J Med, 354, pp. 567-578
Awada, A., Zhang, S., Gil, T., A phase i clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies (2007) Curr Med Res Opin, 23, pp. 991-1003
Li, S., Takasu, T., Perlman, D.M., Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release (2003) J Biol Chem, 278, pp. 3015-3022
Hong, K.O., Kim, J.H., Hong, J.S., Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells (2009) J Exp Clin Cancer Res, 28, p. 28
Bruzzese, F., Leone, A., Rocco, M., HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT (2011) J Cell Physiol, 226, pp. 2378-2390
Toulany, M., Baumann, M., Rodemann, H.P., Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity (2007) Mol Cancer Res, 5, pp. 863-872
Dent, P., Yacoub, A., Contessa, J., Stress and radiation-induced activation of multiple intracellular signaling pathways (2003) Radiat Res, 159, pp. 283-300
Qiu, W., Schönleben, F., Li, X., PIK3CA mutations in head and neck squamous cell carcinoma (2006) Clin Cancer Res, 12, pp. 1441-1446
Lui, V.W., Hedberg, M.L., Li, H., Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers (2013) Cancer Discov, 3, pp. 761-769
Yoshida, K., Sasaki, R., Nishimura, H., Nuclear factor-kappaB expression as a novel marker of radioresistance in early-stage laryngeal cancer (2010) Head Neck, 32, pp. 646-655
Alshareeda, A.T., Negm, O.H., Albarakati, N., Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer (2013) Breast Cancer Res Treat, 139, pp. 301-310
Groselj, B., Kerr, M., Kiltie, A.E., Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression (2013) Radiother Oncol, 108, pp. 429-433
Kuo, M.L., Chuang, S.E., Lin, M.T., Yang, S.Y., The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6 (2001) Oncogene, 20, pp. 677-685
Zhan, M., Han, Z.C., Phosphatidylinositide 3-kinase/AKT in radiation responses (2004) Histol Histopathol, 19, pp. 915-923
Wymann, M.P., Bulgarelli-Leva, G., Zvelebil, M.J., Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction (1996) Mol Cell Biol, 16, pp. 1722-1733
Vlahos, C.J., Matter, W.F., Hui, K.Y., Brown, R.F., A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) (1994) J Biol Chem, 269, pp. 5241-5248
Garlich, J.R., De, P., Dey, N., A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity (2008) Cancer Res, 68, pp. 206-215
Ma, B.B., Lui, V.W., Hui, C.W., Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models (2014) Cancer Lett, 343, pp. 24-32
Hideshima, T., Catley, L., Yasui, H., Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells (2006) Blood, 107, pp. 4053-4062
Argiris, A., Cohen, E., Karrison, T., A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer (2006) Cancer Biol Ther, 5, pp. 766-770
Bauman, J.E., Arias-Pulido, H., Lee, S.J., A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma (2013) Oral Oncol, 49, pp. 461-467
Bhatt, V.R., Ganti, A.K., Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck (2013) Oral Oncol, 49, p. e25
Brown, C.J., Lain, S., Verma, C.S., Fersht, A.R., Lane, D.P., Awakening guardian angels: Drugging the p53 pathway (2009) Nat Rev Cancer, 9, pp. 862-873
Vousden, K.H., Lu, X., Live or let die: The cell's response to p53 (2002) Nat Rev Cancer, 2, pp. 594-604
Gasco, M., Crook, T., The p53 network in head and neck cancer (2003) Oral Oncol, 39, pp. 222-231
Murphy, M., Ahn, J., Walker, K.K., Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a (1999) Genes Dev, 13, pp. 2490-2501
Mihara, M., Erster, S., Zaika, A., P53 has a direct apoptogenic role at the mitochondria (2003) Mol Cell, 11, pp. 577-590
Yu, J., Zhang, L., PUMA, a potent killer with or without p53 (2008) Oncogene, 271, pp. S71-S83
Somers, K.D., Merrick, M.A., Lopez, M.E., Incognito, L.S., Schechter, G.L., Casey, G., Frequent p53 mutations in head and neck cancer (1992) Cancer Res, 52, pp. 5997-6000
Couture, C., Raybaud-Diogène, H., Têtu, B., P53 and Ki-67 as markers of radioresistance in head and neck carcinoma (2002) Cancer, 94, pp. 713-722
Skinner, H.D., Sandulache, V.C., Ow, T.J., TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence (2012) Clin Cancer Res, 18, pp. 290-300
Poeta, M.L., Manola, J., Goldwasser, M.A., TP53 mutations and survival in squamous-cell carcinoma of the head and neck (2007) N Engl J Med, 357, pp. 2552-2561
Csuka, O., Remenár, E., Koronczay, K., Doleschall, Z., Németh, G., Predictive value of p53, Bcl2 and bax in the radiotherapy of head and neck cancer (1997) Pathol Oncol Res, 3, pp. 204-210
Valente, L.J., Gray, D.H., Michalak, E.M., P53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa (2013) Cell Rep, 3, pp. 1339-1345
Yoo, G.H., Moon, J., Leblanc, M., A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: Report of the Southwest Oncology Group (2009) Arch Otolaryngol Head Neck Surg, 135, pp. 869-874
Clayman, G.L., El-Naggar, A.K., Lippman, S.M., Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma (1998) J Clin Oncol, 16, pp. 2221-2232
Nemunaitis, J., Nemunaitis, J., Head and neck cancer: Response to p53-based therapeutics (2011) Head Neck, 33, pp. 131-134
Pearson, S., Jia, H., Kandachi, K., China approves first gene therapy (2004) Nat Biotechnol, 22, pp. 3-4
Tassone, P., Old, M., Teknos, T.N., Pan, Q., P53-based therapeutics for head and neck squamous cell carcinoma (2013) Oral Oncol, 49, pp. 733-737
Nemunaitis, J., Khuri, F., Ganly, I., Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer (2001) J Clin Oncol, 19, pp. 289-298
Ganly, I., Kirn, D., Eckhardt, G., A phase i study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer (2000) Clin Cancer Res, 6, pp. 798-806
Yuki, K., Takahashi, A., Ota, I., Sensitization by glycerol for CDDP-therapy against human cultured cancer cells and tumors bearing mutated p53 gene (2004) Apoptosis, 9, pp. 853-859
Ota, I., Okamoto, N., Yane, K., Therapeutic strategies for head and neck cancer based on p53 status (2012) Exp Ther Med, 3, pp. 585-591
Bykov, V.J., Issaeva, N., Shilov, A., Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound (2002) Nat Med, 8, pp. 282-288
Roh, J.L., Kang, S.K., Minn, I., Califano, J.A., Sidransky, D., Koch, W.M., P53-reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma (2011) Oral Oncol, 47, pp. 8-15
Xie, X., Piao, L., Bullock, B.N., Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma (2014) Oncogene, 33, pp. 1037-1046
Smokeless tobacco and some tobacco-specific N-nitrosamines (2007) IARC Monogr Eval Carcinog Risks Hum, 89, pp. 1-592. , Working Group On The Evaluation Of Carcinogenic Risks To Humans I
Park, B.J., Chiosea, S.I., Grandis, J.R., Molecular changes in the multistage pathogenesis of head and neck cancer (2010) Cancer Biomark, 9, pp. 325-339
Lassen, P., Eriksen, J.G., Hamilton-Dutoit, S., Tramm, T., Alsner, J., Overgaard, J., Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck (2009) J Clin Oncol, 27, pp. 1992-1998
Cattani, P., Hohaus, S., Bellacosa, A., Association between cyclin D1 (CCND1) gene amplification and human papillomavirus infection in human laryngeal squamous cell carcinoma (1998) Clin Cancer Res, 4, pp. 2585-2589
Kostareli, E., Holzinger, D., Hess, J., New concepts for translational head and neck oncology: Lessons from HPV-related oropharyngeal squamous cell carcinomas (2012) Front Oncol, 2, p. 36
Licitra, L., Perrone, F., Bossi, P., High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma (2006) J Clin Oncol, 24, pp. 5630-5636
Kofler, B., Laban, S., Busch, C.J., Lörincz, B., Knecht, R., New treatment strategies for HPV-positive head and neck cancer (2014) Eur Arch Otorhinolaryngol, 271, pp. 1861-1867
Pajares, B., Trigo, J.M., Toledo, M.D., Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer (2013) BMC Cancer, 13, p. 26
Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications
Head and neck squamous cell carcinoma (HNSCC) is strongly associated with alcohol and tobacco consumption. Lately, the incidence of human papillomavirus (HPV)-related tumors has shown a significant increase, and HPV-related tumors show distinctive features if compared with the HPV-negative counterpart. Locally advanced HNSCC can be treated with concomitant chemoradiotherapy, but early recurrences sometimes occur. Relapses are often related to an intrinsic radioresistance of the tumors. Alterations in intracellular pathways, primarily involved in cell proliferation, apoptosis, and DNA repair, can lead to radioresistance. Preclinical and clinical evidence highlighted that 3 main pathways, including the epidermal growth factor receptor (EGFR), the phosphotidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), and the p53 signaling cascades, play a crucial role in radioresistance development. A future approach may consist in the association of radiotherapy (RT) and selective inhibition of the key pathways involved in radioresistance. Phase I, II, and III clinical trials are currently testing these novel treatment strategies. © 2015 Wiley Periodicals, Inc. Head Neck 37: 763-770, 2015 © 2015 Wiley Periodicals, Inc.
Head and neck squamous cell carcinoma (HNSCC) is strongly associated with alcohol and tobacco consumption. Lately, the incidence of human papillomavirus (HPV)-related tumors has shown a significant increase, and HPV-related tumors show distinctive features if compared with the HPV-negative counterpart. Locally advanced HNSCC can be treated with concomitant chemoradiotherapy, but early recurrences sometimes occur. Relapses are often related to an intrinsic radioresistance of the tumors. Alterations in intracellular pathways, primarily involved in cell proliferation, apoptosis, and DNA repair, can lead to radioresistance. Preclinical and clinical evidence highlighted that 3 main pathways, including the epidermal growth factor receptor (EGFR), the phosphotidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), and the p53 signaling cascades, play a crucial role in radioresistance development. A future approach may consist in the association of radiotherapy (RT) and selective inhibition of the key pathways involved in radioresistance. Phase I, II, and III clinical trials are currently testing these novel treatment strategies. © 2015 Wiley Periodicals, Inc. Head Neck 37: 763-770, 2015 © 2015 Wiley Periodicals, Inc.
Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications
| ▼ Biomolecules able to modulate the VEGF-dependent angiogenesis |
Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications
Other filter: ([btitle,keywords] "Chemoradiotherapy" O ...
Fasano M, Perri F, Della Corte CM, Di Liello R, Della Vittoria Scarpati G, Cascella M, Ottaiano A, Ciardiello F, Solla R
* Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors (10 views)
Biomedicines (ISSN: 2227-9059linking), 2021 Aug 19; 9(8): N/D-N/D.
Impact Factor: 4.757
View Export to BibTeX Export to EndNote
Perri F, Longo F, Della Vittoria Scarpati G, Pisconti S, Longo V, Addeo R, Carducci F, Buonerba C, Fulciniti F, Solla R
* Metastatic HPV-related oropharyngeal carcinoma cured with chemoradiotherapy: importance of pretherapy biomolecular assessment (307 views)
Clin Case Rep (ISSN: 2050-0904print, 2050-0904linking), 2017 Nov 24; 6(1): 56-62.
Impact Factor: 0.54
View Export to BibTeX Export to EndNote
Cella L, D'Avino V, Palma G, Conson M, Liuzzi R, Picardi M, Pressello MC, Boboc GI, Battistini R, Donato V, Pacelli R
* Modeling the risk of radiation-induced lung fibrosis: Irradiated heart tissue is as important as irradiated lung (415 views) (PDF 197 views)
Radiother Oncol (ISSN: 0167-8140, 1879-0887, 0167-8140linking), 2015 Aug 12; 117(1): 36-43.
Impact Factor: 4.817
View Export to BibTeX Export to EndNote
Cella L, Oh JH, Deasy JO, Palma G, Liuzzi R, D'Avino V, Conson M, Picardi M, Salvatore M, Pacelli R
* Predicting radiation-induced valvular heart damage (334 views)
Acta Oncol (ISSN: 0284-186x, 0284-186xlinking), 2015 Mar 24; 54(10): 1796-1804.
Impact Factor: 3.73
View Export to BibTeX Export to EndNote
D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, Silvestro L, Pacelli R, Napolitano M, Iaffaioli RV, Scala S
* A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients (441 views)
Int J Cancer (ISSN: 0020-7136), 2014 Jul 15; 135(2): 379-390.
Impact Factor: 5.085
View Export to BibTeX Export to EndNote
Orditura M, Galizia G, Di Martino N, Ancona E, Castoro C, Pacelli R, Morgillo F, Rossetti S, Gambardella V, Farella A, Laterza MM, Ruol A, Fabozzi A, Napolitano V, Iovino F, Lieto E, Fei L, Conzo G, Ciardiello F, De Vita F
* Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study (1873 views)
Curr Oncol (ISSN: 1198-0052, 1718-7729electronic, 1198-0052linking), 2014 Jun; 21(3): 125-133.
Impact Factor: 1.785
View Export to BibTeX Export to EndNote
Cella L, Liuzzi R, D'Avino V, Conson M, Di Biase A, Picardi M, Pugliese N, Solla R, Salvatore M, Pacelli R
* Pulmonary damage in Hodgkin's lymphoma patients treated with sequential chemo-radiotherapy: Predictors of radiation-induced lung injury (379 views)
Acta Oncol (ISSN: 0284-186x), 2014 May; 53(5): 613-619.
Impact Factor: 2.997
View Export to BibTeX Export to EndNote
Pedicini P, Fiorentino A, Improta G, Nappi A, Salvatore M, Storto G
* Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma (291 views)
Clin Transl Oncol (ISSN: 1699-048x), 2013 Nov; 15(11): 919-924.
Impact Factor: 1.6
View Export to BibTeX Export to EndNote
Cella L, Liuzzi R, Conson M, D'Avino V, Salvatore M, Pacelli R
* Multivariate normal tissue complication probability modeling of heart valve dysfunction in Hodgkin lymphoma survivors (435 views)
Int J Radiat Oncol (ISSN: 0360-3016, 1879-355x, 1879-355xelectronic), 2013 Oct 1; 87(2): 304-310.
Impact Factor: 4.176
View Export to BibTeX Export to EndNote
Cella L, Conson M, Liuzzi R, Pacelli R
* In regard to boomsma et al (354 views)
Int J Radiat Oncol (ISSN: 0360-3016, 1879-355x, 1879-355xelectronic), 2013 Jan 1; 85(1): 11-11.
Impact Factor: 4.176
View Export to BibTeX Export to EndNote
Cella L, Liuzzi R, Conson M, D'Avino V, Salvatore M, Pacelli R
* Development of multivariate NTCP models for radiation-induced hypothyroidism: A comparative analysis (446 views) (PDF 236 views)
Radiat Oncol Radiation Oncology (ISSN: 1748-717x), 2012 Dec 27; 7(1): 224-224.
Impact Factor: 2.107
View Export to BibTeX Export to EndNote
Pedicini P, Nappi A, Strigari L, Jereczek-Fossa BA, Alterio D, Cremonesi M, Botta F, Vischioni B, Caivano R, Fiorentino A, Improta G, Storto G, Benassi M, Orecchia R, Salvatore M
* Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma (491 views)
Radiation Oncology (ISSN: 1748-717x), 2012 Sep 24; 7: 143-143.
Impact Factor: 2.107
View Export to BibTeX Export to EndNote
Cella L, Conson M, Caterino M, De Rosa N, Liuzzi R, Picardi M, Grimaldi F, Solla R, Farella A, Salvatore M, Pacelli R
* Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin's lymphoma (493 views) (PDF 236 views)
Int J Radiat Oncol (ISSN: 0360-3016, 1879-355x, 1879-355xelectronic), 2012 Apr 1; 82(5): 1802-1808.
Impact Factor: 4.524
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S
* 3'-deoxy-3'-18F-fluorothymidine (FLT) PET/CT to guide therapy with epidermal growth factor receptor (EGFR) antagonists and Bcl-xL inhibitors in non-small cell lung cancer (616 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Impact Factor: 5.774
View Export to BibTeX Export to EndNote
Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, Di Martino N, Pacelli R, Renda A, Ciardiello F, De Vita F
* Complete Response To Preoperative Chemoradiation And Survival In Esophageal Cancer: A Pooled Analysis Of Three Single-Institution Phase Ii Trials (394 views)
Diseases Of The Esophagus, 2012 Feb; 142(5): 130-136.
Impact Factor: 2.057
View Export to BibTeX Export to EndNote
Diana D, Basile A, De Rosa L, Di Stasi R, Auriemma S, Arra C, Pedone C, Turco MC, Fattorusso R, D'Andrea LD
* Beta-Hairpin Peptide That Targets Vascular Endothelial Growth Factor (vegf) Receptors: Design, Nmr Characterization, And Biological Activity (620 views)
Jbc Papers (ISSN: 1083-351x, 0021-9258, 0021-9258linking), 2011 Dec 2; 286(48): 41680-41691.
Impact Factor: 4.773
View Export to BibTeX Export to EndNote
Cella L, Liuzzi R, Conson M, Torre G, Caterino M, De Rosa N, Picardi M, Camera L, Solla R, Farella A, Salvatore M, Pacelli R
* Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin's lymphoma (470 views)
Radiother Oncol (ISSN: 0167-8140, 1879-0887, 1879-0887electronic), 2011 Nov; 101(2): 316-321.
Impact Factor: 5.58
View Export to BibTeX Export to EndNote
Orditura M, Galizia G, Napolitano V, Martinelli E, Pacelli R, Lieto E, Aurilio G, Vecchione L, Morgillo F, Catalano G, Ciardiello F, Del Genio A, Di Martino N, De Vita F
* Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study (351 views)
Cancer Investigation (ISSN: 0735-7907), 2010 Oct; 28(8): 820-827.
Impact Factor: 2.39
View Export to BibTeX Export to EndNote
Carlomagno C, Farella A, Bucci L, D'Armiento FP, Pesce G, Pepe S, Cannella L, Pacelli R, De Stefano A, Solla R, D'Armiento MR, De Placido S
* Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: A phase II study (735 views)
Annals Of Oncology (ISSN: 0923-7534), 2009 May; 20(5): 906-912.
Impact Factor: 5.647
View Export to BibTeX Export to EndNote
* Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors (10 views)
Biomedicines (ISSN: 2227-9059linking), 2021 Aug 19; 9(8): N/D-N/D.
Impact Factor: 4.757
View Export to BibTeX Export to EndNote
Perri F, Longo F, Della Vittoria Scarpati G, Pisconti S, Longo V, Addeo R, Carducci F, Buonerba C, Fulciniti F, Solla R
* Metastatic HPV-related oropharyngeal carcinoma cured with chemoradiotherapy: importance of pretherapy biomolecular assessment (307 views)
Clin Case Rep (ISSN: 2050-0904print, 2050-0904linking), 2017 Nov 24; 6(1): 56-62.
Impact Factor: 0.54
View Export to BibTeX Export to EndNote
Cella L, D'Avino V, Palma G, Conson M, Liuzzi R, Picardi M, Pressello MC, Boboc GI, Battistini R, Donato V, Pacelli R
* Modeling the risk of radiation-induced lung fibrosis: Irradiated heart tissue is as important as irradiated lung (415 views) (PDF 197 views)
Radiother Oncol (ISSN: 0167-8140, 1879-0887, 0167-8140linking), 2015 Aug 12; 117(1): 36-43.
Impact Factor: 4.817
View Export to BibTeX Export to EndNote
Cella L, Oh JH, Deasy JO, Palma G, Liuzzi R, D'Avino V, Conson M, Picardi M, Salvatore M, Pacelli R
* Predicting radiation-induced valvular heart damage (334 views)
Acta Oncol (ISSN: 0284-186x, 0284-186xlinking), 2015 Mar 24; 54(10): 1796-1804.
Impact Factor: 3.73
View Export to BibTeX Export to EndNote
D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, Silvestro L, Pacelli R, Napolitano M, Iaffaioli RV, Scala S
* A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients (441 views)
Int J Cancer (ISSN: 0020-7136), 2014 Jul 15; 135(2): 379-390.
Impact Factor: 5.085
View Export to BibTeX Export to EndNote
Orditura M, Galizia G, Di Martino N, Ancona E, Castoro C, Pacelli R, Morgillo F, Rossetti S, Gambardella V, Farella A, Laterza MM, Ruol A, Fabozzi A, Napolitano V, Iovino F, Lieto E, Fei L, Conzo G, Ciardiello F, De Vita F
* Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study (1873 views)
Curr Oncol (ISSN: 1198-0052, 1718-7729electronic, 1198-0052linking), 2014 Jun; 21(3): 125-133.
Impact Factor: 1.785
View Export to BibTeX Export to EndNote
Cella L, Liuzzi R, D'Avino V, Conson M, Di Biase A, Picardi M, Pugliese N, Solla R, Salvatore M, Pacelli R
* Pulmonary damage in Hodgkin's lymphoma patients treated with sequential chemo-radiotherapy: Predictors of radiation-induced lung injury (379 views)
Acta Oncol (ISSN: 0284-186x), 2014 May; 53(5): 613-619.
Impact Factor: 2.997
View Export to BibTeX Export to EndNote
Pedicini P, Fiorentino A, Improta G, Nappi A, Salvatore M, Storto G
* Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma (291 views)
Clin Transl Oncol (ISSN: 1699-048x), 2013 Nov; 15(11): 919-924.
Impact Factor: 1.6
View Export to BibTeX Export to EndNote
Cella L, Liuzzi R, Conson M, D'Avino V, Salvatore M, Pacelli R
* Multivariate normal tissue complication probability modeling of heart valve dysfunction in Hodgkin lymphoma survivors (435 views)
Int J Radiat Oncol (ISSN: 0360-3016, 1879-355x, 1879-355xelectronic), 2013 Oct 1; 87(2): 304-310.
Impact Factor: 4.176
View Export to BibTeX Export to EndNote
Cella L, Conson M, Liuzzi R, Pacelli R
* In regard to boomsma et al (354 views)
Int J Radiat Oncol (ISSN: 0360-3016, 1879-355x, 1879-355xelectronic), 2013 Jan 1; 85(1): 11-11.
Impact Factor: 4.176
View Export to BibTeX Export to EndNote
Cella L, Liuzzi R, Conson M, D'Avino V, Salvatore M, Pacelli R
* Development of multivariate NTCP models for radiation-induced hypothyroidism: A comparative analysis (446 views) (PDF 236 views)
Radiat Oncol Radiation Oncology (ISSN: 1748-717x), 2012 Dec 27; 7(1): 224-224.
Impact Factor: 2.107
View Export to BibTeX Export to EndNote
Pedicini P, Nappi A, Strigari L, Jereczek-Fossa BA, Alterio D, Cremonesi M, Botta F, Vischioni B, Caivano R, Fiorentino A, Improta G, Storto G, Benassi M, Orecchia R, Salvatore M
* Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma (491 views)
Radiation Oncology (ISSN: 1748-717x), 2012 Sep 24; 7: 143-143.
Impact Factor: 2.107
View Export to BibTeX Export to EndNote
Cella L, Conson M, Caterino M, De Rosa N, Liuzzi R, Picardi M, Grimaldi F, Solla R, Farella A, Salvatore M, Pacelli R
* Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin's lymphoma (493 views) (PDF 236 views)
Int J Radiat Oncol (ISSN: 0360-3016, 1879-355x, 1879-355xelectronic), 2012 Apr 1; 82(5): 1802-1808.
Impact Factor: 4.524
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S
* 3'-deoxy-3'-18F-fluorothymidine (FLT) PET/CT to guide therapy with epidermal growth factor receptor (EGFR) antagonists and Bcl-xL inhibitors in non-small cell lung cancer (616 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Impact Factor: 5.774
View Export to BibTeX Export to EndNote
Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, Di Martino N, Pacelli R, Renda A, Ciardiello F, De Vita F
* Complete Response To Preoperative Chemoradiation And Survival In Esophageal Cancer: A Pooled Analysis Of Three Single-Institution Phase Ii Trials (394 views)
Diseases Of The Esophagus, 2012 Feb; 142(5): 130-136.
Impact Factor: 2.057
View Export to BibTeX Export to EndNote
Diana D, Basile A, De Rosa L, Di Stasi R, Auriemma S, Arra C, Pedone C, Turco MC, Fattorusso R, D'Andrea LD
* Beta-Hairpin Peptide That Targets Vascular Endothelial Growth Factor (vegf) Receptors: Design, Nmr Characterization, And Biological Activity (620 views)
Jbc Papers (ISSN: 1083-351x, 0021-9258, 0021-9258linking), 2011 Dec 2; 286(48): 41680-41691.
Impact Factor: 4.773
View Export to BibTeX Export to EndNote
Cella L, Liuzzi R, Conson M, Torre G, Caterino M, De Rosa N, Picardi M, Camera L, Solla R, Farella A, Salvatore M, Pacelli R
* Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin's lymphoma (470 views)
Radiother Oncol (ISSN: 0167-8140, 1879-0887, 1879-0887electronic), 2011 Nov; 101(2): 316-321.
Impact Factor: 5.58
View Export to BibTeX Export to EndNote
Orditura M, Galizia G, Napolitano V, Martinelli E, Pacelli R, Lieto E, Aurilio G, Vecchione L, Morgillo F, Catalano G, Ciardiello F, Del Genio A, Di Martino N, De Vita F
* Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study (351 views)
Cancer Investigation (ISSN: 0735-7907), 2010 Oct; 28(8): 820-827.
Impact Factor: 2.39
View Export to BibTeX Export to EndNote
Carlomagno C, Farella A, Bucci L, D'Armiento FP, Pesce G, Pepe S, Cannella L, Pacelli R, De Stefano A, Solla R, D'Armiento MR, De Placido S
* Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: A phase II study (735 views)
Annals Of Oncology (ISSN: 0923-7534), 2009 May; 20(5): 906-912.
Impact Factor: 5.647
View Export to BibTeX Export to EndNote
19 Records (18 excluding Abstracts).
Total impact factor: 68.622 (66.515 excluding Abstracts).
Total 5 year impact factor: 64.635 (62.149 excluding Abstracts).
Total impact factor: 68.622 (66.515 excluding Abstracts).
Total 5 year impact factor: 64.635 (62.149 excluding Abstracts).
524 views. Last view on Saturday 22 April 2023, 22:49:55
ibb.cnr.it
